#Curium's #radioligandtherapy #Bexlutry has been approved in the US as a #generic – or 'radioligand equivalent' (#RLE) – of Novartis' #gastroenteropancreaticneuroendocrinetumour (GEP-NET) therapy Lutathera.

pharmaphorum.com/news/fda-bac...

Norroy Bioscience has received NMPA clearance to begin a pivotal Phase III trial of its PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer.

#Oncology #RadioligandTherapy #Biotech

Disclaimer: This is NOT a financial advice